Skip to content Carb-X
Carb-X
Boston University
Mobile Menu Toggle navigation
  • Sign Up
  • Contact
  • Twitter
  • LinkedIn
Carb-X
Boston University
Boston University
  • About CARB-X
    • Overview
    • Global Threat
    • Our Strategy
    • Stewardship and Access
    • Management & Staff
    • Joint Oversight Board
    • Advisory Board
    • Careers
    • Annual Reports
    • Boston University
  • Portfolio
    • Portfolio Product Developers
    • Portfolio-Pipeline
    • CARB-X Graduates
    • Spotlight on Science
    • Portfolio Acceleration Tools
  • Partners
    • Funding Partners
    • Global Accelerator Network
  • Apply
    • Funding Themes
    • Omnibus Solicitation
    • Application Process
    • Entering Portfolio
    • Apply Here
    • Applicant Questions
  • Resources
    • CARB-X Connect
    • Presentations
    • Videos
    • Publications
    • Education
    • PD Resources
    • Media Resources
  • News
    • CARB-X News
    • In the News
    • Antibiotic Resistance
  • Events
  • About CARB-X
    • Overview
    • Global Threat
    • Our Strategy
    • Stewardship and Access
    • Management & Staff
    • Joint Oversight Board
    • Advisory Board
    • Careers
    • Annual Reports
    • Boston University
  • Portfolio
    • Portfolio Product Developers
    • Portfolio-Pipeline
    • CARB-X Graduates
    • Spotlight on Science
    • Portfolio Acceleration Tools
  • Partners
    • Funding Partners
    • Global Accelerator Network
  • Apply
    • Funding Themes
    • Omnibus Solicitation
    • Application Process
    • Entering Portfolio
    • Apply Here
    • Applicant Questions
  • Resources
    • Presentations
    • Videos
    • Publications
    • Education
    • PD Resources
    • Media Resources
  • News
    • CARB-X News
    • In the News
    • Antibiotic Resistance
  • Events
  • Contact
  • Legal

Portfolio Company

  • Portfolio
  • >
  • Gallery
Idorsia

Idorsia, Allschwil, Switzerland
http://www.idorsia.com

VXN-319
MULTIVALENT VACCINE TARGETING KLEBSIELLA PNEUMONIAE

Prophylactic semi-synthetic O antigen conjugate vaccine
Klebsiella pneumoniae is a superbug that has spread around the world. Incidence of virtually all strains, including those with multi-resistant profiles, is increasing rapidly. Prevention of infection is a critical component to its abatement. Idorsia is developing a multivalent conjugate vaccine with synthetically produced O-antigens to target more than 80% of carbapenem resistant strains. Efficacy of valencies has already been demonstrated in various mouse and rabbit infection models. The work performed with CARB-X support, initiated with Vaxxilon, includes completion of lead optimization and preclinical development, GMP manufacturing, and a Phase I clinical trial.

Current Development Stage: Hit to Lead

CARB-X Investment: Initial investment of up to $1.4m with potential option payments up to $3.1m

Initial CARB-X Investment Date: April 1, 2019

Carb-X

Led by Boston University

Copyright 2023

  • Contact
  • Careers
  • Site Credits
  • Legal
  • Twitter
  • LinkedIn

Copyright 2023